Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00848250 · ClinicalTrials.gov registry record · NA

Angiotensin Converting Enzyme Inhibitors During Cardiopulmonary Bypass in Infants and Children

A NA study of Congenital Heart Disease, sponsored by Vanderbilt University Medical Center.

Completed
Registry status
NA
Development phase
21
Enrollment target
1
Study location

NCT00848250 is a NA study of Congenital Heart Disease that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 21 participants, below the 474-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00848250, a NA study of Congenital Heart Disease, has completed, sponsored by Vanderbilt University Medical Center.

COMPLETED
Registry status
NA
Development phase
21 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether ACE inhibitors alter the fibrinolytic, inflammatory, and hemodynamic response to cardiopulmonary bypass in infants and children with congenital heart disease.

Conditions Studied

Interventions

  • DRUG Angiotensin Converting Enzyme Inhibitor
  • OTHER No ACE Inhibitor

Study Locations (1)

Tennessee

  • Monroe Carell Jr. Children's Hospital at Vanderbilt - Nashville

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2008-09
Est. Completion 2010-07
Phase NA

What the Registry Record Tells You About NCT00848250

The ClinicalTrials.gov registry entry for NCT00848250 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 474-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (96% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Congenital Heart Disease appearing as the primary indexed condition, and to 2 interventions - of which Angiotensin Converting Enzyme Inhibitor is the first listed.

NCT00848250 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT00848250 about?

NCT00848250 is a clinical study titled "Angiotensin Converting Enzyme Inhibitors During Cardiopulmonary Bypass in Infants and Children". The purpose of this study is to determine whether ACE inhibitors alter the fibrinolytic, inflammatory, and hemodynamic response to cardiopulmonary bypass in infants and children with congenital heart disease.

What is the current status of trial NCT00848250?

This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2008-09. Estimated completion is 2010-07.

What conditions does trial NCT00848250 study?

This clinical trial studies the following conditions: Congenital Heart Disease.

What interventions are being tested in trial NCT00848250?

The interventions under investigation include: Angiotensin Converting Enzyme Inhibitor (DRUG), No ACE Inhibitor (OTHER).

Who is sponsoring clinical trial NCT00848250?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00848250 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Congenital Heart Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.